Clariant's Healthcare Packaging unit is launching a family of standard desiccant packets produced from its plant in Dongguan, China.

In addition to enabling quick delivery in local markets, the new manufacturing operation can provide critical back up for Clariant's other global sites, should it ever be required, stated the Switzerland specialty chemicals company.

"Business Continuity Planning or BCP is critical to our pharmaceutical stakeholders who are more and more requiring that we have strong contingencies," said Matthias Brommer, Vice President and Head of Clariant Healthcare Packaging. "Accordingly, we are developing a global infrastructure that ensures that we are prepared to deal with any market or operational disruptions."

The Dongguan plant applies the same materials, specifications, quality standards, good manufacturing practices and controls as Clariant's other global production sites in Belen, New Mexico, US, and Romorantin, France, according to the company.

Compliance protocol is also the same, and pharmaceutical desiccants produced in Dongguan comply with US Food & Drug Administration (FDA) and EU standards for contact with food.

In Dongguan, Clariant will produce its global desiccant brands Sorb-it (silica gel) and Tri-Sorb (molecular sieve) desiccant packets, and include Tyvek and Continu-Strip hole punch packets that feature a hole in every seal to optimize the desiccant insertion process.

Clariant's network of production sites will soon include a fourth facility in Cuddalore, India that broke ground recently. Also integral for BCP, the new plant in Cuddalore will supply the large and growing Indian market, the largest producer of generic drugs globally.

"The trend in this market is to require BCP, and Clariant is the only desiccant manufacturer with such an extensive global footprint that both enables production of identical products at multiple sites while improving our service to our global customers," said Brommer.

Clariant's Healthcare Packaging unit is launching a family of standard desiccant packets produced from its plant in Dongguan, China.

In addition to enabling quick delivery in local markets, the new manufacturing operation can provide critical back up for Clariant's other global sites, should it ever be required, stated the Switzerland specialty chemicals company.

"Business Continuity Planning or BCP is critical to our pharmaceutical stakeholders who are more and more requiring that we have strong contingencies," said Matthias Brommer, Vice President and Head of Clariant Healthcare Packaging. "Accordingly, we are developing a global infrastructure that ensures that we are prepared to deal with any market or operational disruptions."

The Dongguan plant applies the same materials, specifications, quality standards, good manufacturing practices and controls as Clariant's other global production sites in Belen, New Mexico, US, and Romorantin, France, according to the company.

Compliance protocol is also the same, and pharmaceutical desiccants produced in Dongguan comply with US Food & Drug Administration (FDA) and EU standards for contact with food.

In Dongguan, Clariant will produce its global desiccant brands Sorb-it (silica gel) and Tri-Sorb (molecular sieve) desiccant packets, and include Tyvek and Continu-Strip hole punch packets that feature a hole in every seal to optimize the desiccant insertion process.

Clariant's network of production sites will soon include a fourth facility in Cuddalore, India that broke ground recently. Also integral for BCP, the new plant in Cuddalore will supply the large and growing Indian market, the largest producer of generic drugs globally.

"The trend in this market is to require BCP, and Clariant is the only desiccant manufacturer with such an extensive global footprint that both enables production of identical products at multiple sites while improving our service to our global customers," said Brommer.